elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q39380445-BD4A47E0-2B88-4EEF-877F-FB6ED798D76A
Q39380445-BD4A47E0-2B88-4EEF-877F-FB6ED798D76A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q39380445-BD4A47E0-2B88-4EEF-877F-FB6ED798D76A
Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?
P2860
Q39380445-BD4A47E0-2B88-4EEF-877F-FB6ED798D76A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q39380445-BD4A47E0-2B88-4EEF-877F-FB6ED798D76A
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
f6776c5f2ba9c0dc9b1604f674ff56fe0f73e500
P2860
Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.